Not yet medically reviewed, information on this site is in preparation and has not been verified by a medical reviewer.
Legality · HHC

HHC in Sri Lanka: not individually verified

Not individually verified

We have not confirmed that HHC specifically is scheduled in Sri Lanka, so this page gives no legal status. Publishing a guess here would be worse than publishing nothing. What we do know is the governing national drug law, below.

What is on record
Not confirmed as a dangerous drug under Sri Lanka's Poisons, Opium and Dangerous Drugs Ordinance (Chapter 218): not named anywhere in the Third Schedule; reachable only through Section 2 clause 4 or clause 5, or by reading the item 1 entry for cannabinol derivatives to include it, and each of those turns on a court's assessment. Hexahydrocannabinol is absent by name. The cannabinoid entries are enumerated: cannabinol and its derivatives at Section 2 item 1, six named tetrahydrocannabinol isomers at item 33, dronabinol at item 46 and parahexyl at item 24. HHC is none of them by name, and it is not a tetrahydrocannabinol isomer, because hydrogenation changes the formula rather than rearranging it. The model: the list is inside the Ordinance and the power to change it is delegated, with a parliamentary lock on the delegation. Section 48 provides that 「the drugs, substances, articles or preparations, specified for the time being in Groups A, B, C, D and E in Part I of the Third Schedule, shall be deemed to be dangerous drugs」. Section 2(1) then provides that 「regulation」 means a regulation made under this Ordinance and published in the Gazette, 「and includes the First, Second, Third, Fourth, Fifth and Sixth Schedules」, so the Third Schedule is itself a regulation. The empowering section is section 80. Section 80(2)(b) lets the Minister make regulations 「for adding any item to or deleting any item from, or altering, varying or amending in any other way, any of the lists or Groups of poisons and dangerous drugs set out in the First and Third Schedules」, and section 80(3) then provides that 「No regulation so made shall have effect unless it has been approved by Parliament and notification of such approval has been published in the Gazette」. So the delegation is real but it is locked to an affirmative vote, and in practice the 2022 changes were made by primary legislation rather than by regulation. The Act was last amended by the Poisons, Opium and Dangerous Drugs (Amendment) Act, No. 7 of 2026, certified 6 March 2026. The Third Schedule was last amended by section 6 of the Poisons, Opium and Dangerous Drugs (Amendment) Act, No. 41 of 2022, certified 23 November 2022 and published as a supplement to Part II of the Gazette of 25 November 2022, which substituted Group B of Part I and the whole of Part III. Act No. 7 of 2026 does not touch the Third Schedule. Re-read on 3 October 2026. The Ordinance, Act No. 41 of 2022 and Act No. 7 of 2026 were fetched again that day, and the Third Schedule was read as it stands after Act No. 41 of 2022. Act No. 7 of 2026 amends sections 54B, 78, 83, 84, 85, 86 and 87, inserts section 54AA, and amends no Schedule. No later amending instrument was found on the National Dangerous Drugs Control Board's list of acts or by search on 3 October 2026, which does not rule out a later gazette. Section 3 clause 13, the synthetic cannabinoid clause, does not reach it either. Its four scaffolds are a 3-(1-naphthylmethyl)indole, a 3-(1-naphthoyl)pyrrole, a naphthylideneindene and a 「2-(3-hydroxycyclohexyl)phenol structure」. Hexahydrocannabinol has no naphthyl group, and the cyclohexane ring of its dibenzopyran carries a methyl group at position 9 and no hydroxy group, so it does not present the hydroxycyclohexyl phenol that the fourth scaffold requires. The international position has moved and the domestic list has not. The Commission on Narcotic Drugs, at its 68th session from 10 to 14 March 2025, added hexahydrocannabinol to Schedule II of the Convention on Psychotropic Substances of 1971, and UNODC records that the decision entered into force on 6 December 2025. Section 48 makes a substance a dangerous drug only by specification in the Third Schedule, and no Sri Lankan instrument read for this cell specifies it, so the treaty placement is not itself a domestic placement. The item 1 entry, 「Cannabinol and cannabinol derivatives (CBN)」, is a weak route for hexahydrocannabinol: the schedule names tetrahydrocannabinol separately at item 33 and dronabinol at item 46, which it would not need to do if item 1 already swept in the reduced cannabinoids, so this cell does not rely on item 1.

Confirm directly with Sri Lanka’s national drug authority or your own embassy before you rely on anything.

What Sri Lanka HAS confirmed for related substances

This page is deliberately excluded from search indexing and from our sitemap. Only confirmed, individually verified statuses are published as indexable pages.